Hims & Hers Health, Inc. HIMS announced that eligible customers can now access six months of prescription-only Wegovy at a ...

Hims & Hers (NYSE: HIMS) has put investors on a roller coaster ride in 2025. *Stock prices used were the afternoon prices of ...

We recently published a list of 10 Stocks Got Wiped Out. Are You Holding Any? In this article, we are going to take a look at ...

Investors are buying Hims & Hers Health ( HIMS 10.09%) stock hand over fist after the mail-order drugs company reported an earnings miss but a sales beat last night. But they're selling off shares of ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.3% in the afternoon session after Cigna Group's Evernorth ...

Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

Hims & Hers Health continues to fire on all cylinders as a business. Click here to read why HIMS stock is a Buy.

Hims & Hers beat first-quarter profit and revenue forecasts as sales more than doubled. However, the health and wellness platform missed analysts' estimates for current-quarter sales on the impact of ...

Health and wellness company, which sold alternatives to weight-loss drugs like Wegovy, is now collaborating with Wegovy-maker Novo Nordisk.

Hims & Hers Health (NYSE: HIMS) stock surged 23% on Tuesday, April 29, following Novo Nordisk’s announcement that it will offer its popular weight loss drug Wegovy through select telehealth ...

See: Buy Or Sell Nvidia Stock Ahead Of Earnings? Nevertheless, Hims & Hers’ projection for Q2 revenue, with a midpoint of $540 million, fell short of the $565 million consensus forecast.